Logo image of ANVS

ANNOVIS BIO (ANVS) Stock Fundamental Analysis

USA - NYSE:ANVS - US03615A1088 - Common Stock

3.1 USD
+0.76 (+32.48%)
Last: 11/17/2025, 10:32:09 AM
Fundamental Rating

2

Taking everything into account, ANVS scores 2 out of 10 in our fundamental rating. ANVS was compared to 533 industry peers in the Biotechnology industry. While ANVS has a great health rating, there are worries on its profitability. ANVS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ANVS had negative earnings in the past year.
In the past year ANVS has reported a negative cash flow from operations.
ANVS had negative earnings in each of the past 5 years.
In the past 5 years ANVS always reported negative operating cash flow.
ANVS Yearly Net Income VS EBIT VS OCF VS FCFANVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

ANVS's Return On Assets of -141.04% is on the low side compared to the rest of the industry. ANVS is outperformed by 83.86% of its industry peers.
The Return On Equity of ANVS (-165.08%) is worse than 64.54% of its industry peers.
Industry RankSector Rank
ROA -141.04%
ROE -165.08%
ROIC N/A
ROA(3y)-265.83%
ROA(5y)-179.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANVS Yearly ROA, ROE, ROICANVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

ANVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANVS Yearly Profit, Operating, Gross MarginsANVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for ANVS has been increased compared to 1 year ago.
The number of shares outstanding for ANVS has been increased compared to 5 years ago.
ANVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANVS Yearly Shares OutstandingANVS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ANVS Yearly Total Debt VS Total AssetsANVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ANVS has an Altman-Z score of -1.31. This is a bad value and indicates that ANVS is not financially healthy and even has some risk of bankruptcy.
ANVS has a Altman-Z score (-1.31) which is in line with its industry peers.
ANVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.31
ROIC/WACCN/A
WACCN/A
ANVS Yearly LT Debt VS Equity VS FCFANVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 7.65 indicates that ANVS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.65, ANVS is in the better half of the industry, outperforming 72.61% of the companies in the same industry.
ANVS has a Quick Ratio of 7.65. This indicates that ANVS is financially healthy and has no problem in meeting its short term obligations.
ANVS has a Quick ratio of 7.65. This is in the better half of the industry: ANVS outperforms 72.80% of its industry peers.
Industry RankSector Rank
Current Ratio 7.65
Quick Ratio 7.65
ANVS Yearly Current Assets VS Current LiabilitesANVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.45% over the past year.
EPS 1Y (TTM)52.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ANVS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.24% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.5%
EPS Next 2Y14.78%
EPS Next 3Y11.28%
EPS Next 5Y12.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANVS Yearly Revenue VS EstimatesANVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M
ANVS Yearly EPS VS EstimatesANVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANVS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANVS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANVS Price Earnings VS Forward Price EarningsANVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANVS Per share dataANVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.78%
EPS Next 3Y11.28%

More info and screens

0

5. Dividend

5.1 Amount

ANVS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANNOVIS BIO

NYSE:ANVS (11/17/2025, 10:32:09 AM)

3.1

+0.76 (+32.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-19 2026-03-19/bmo
Inst Owners14.49%
Inst Owner Change10.03%
Ins Owners14.81%
Ins Owner Change2.99%
Market Cap74.86M
Revenue(TTM)N/A
Net Income(TTM)-30.26M
Analysts80
Price Target14.03 (352.58%)
Short Float %6.11%
Short Ratio1.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.01%
Min EPS beat(2)11.97%
Max EPS beat(2)22.06%
EPS beat(4)2
Avg EPS beat(4)-18.58%
Min EPS beat(4)-80.79%
Max EPS beat(4)22.06%
EPS beat(8)4
Avg EPS beat(8)-6.42%
EPS beat(12)7
Avg EPS beat(12)-18.16%
EPS beat(16)8
Avg EPS beat(16)-29.65%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.15%
EPS NY rev (1m)-1.13%
EPS NY rev (3m)21.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.08
P/tB 4.08
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS0
BVpS0.76
TBVpS0.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -141.04%
ROE -165.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-265.83%
ROA(5y)-179.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.65
Quick Ratio 7.65
Altman-Z -1.31
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y29.5%
EPS Next 2Y14.78%
EPS Next 3Y11.28%
EPS Next 5Y12.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.18%
EBIT Next 3Y-44.37%
EBIT Next 5Y-5.41%
FCF growth 1Y14.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.32%
OCF growth 3YN/A
OCF growth 5YN/A

ANNOVIS BIO / ANVS FAQ

Can you provide the ChartMill fundamental rating for ANNOVIS BIO?

ChartMill assigns a fundamental rating of 2 / 10 to ANVS.


Can you provide the valuation status for ANNOVIS BIO?

ChartMill assigns a valuation rating of 0 / 10 to ANNOVIS BIO (ANVS). This can be considered as Overvalued.


What is the profitability of ANVS stock?

ANNOVIS BIO (ANVS) has a profitability rating of 0 / 10.


What is the financial health of ANNOVIS BIO (ANVS) stock?

The financial health rating of ANNOVIS BIO (ANVS) is 7 / 10.